Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Cancerimmunterapi til behandling af hæmatologisk cancer

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Androgent insensitivitetssyndrom opdaget pga. diskordans mellem prænatale vurderinger af fosterkøn.

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Behandling af tymom og thymuskarcinom

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Bilateral caput femoris-epifysiolyse efter epileptisk anfald

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Osmotisk demyeliniseringssyndrom

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Uafklaret dyspnø.

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. The real-world outcome of metastatic melanoma: Unknown primary vs. known cutaneous

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Tumor necrosis factor induces rapid down-regulation of TXNIP in human T cells

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope

    Research output: Contribution to journalReviewResearchpeer-review

  4. Chimeric antigen receptor-T-cellebehandling

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Terapeutisk cancervaccination mod hæmatologisk cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Cancer immune therapy is now used routinely for the treatment of several solid malignancies, albeit just recently having entered the clinic for treatment of haematological malignancies. Several studies demonstrate that cancer immune therapy is a promising treatment modality for the latter. Especially treatment with chimeric antigen receptor T cells for acute lymphoblastic leukaemia and lymphoma is promising. Other promising treatment modalities are immune check point inhibitors for both lymphoid and myeloid malignancies, as well as therapeutic cancer vaccination targeting tumour antigens.

Translated title of the contributionCancer immune therapy for the treatment of haematological malignancies
Original languageDanish
JournalUgeskrift for Laeger
Volume181
Issue number10
ISSN0041-5782
Publication statusPublished - 4 Mar 2019

ID: 57730184